When will generic briviact be available?

When does generic Briviact (brivaracetam) come to market?

Generic versions of Briviact are expected to become available only after relevant patent and exclusivity protections expire. Those protections can include patents on the drug substance and patents on specific formulations or uses, plus any regulatory exclusivity that delays generic approval.

Because the exact timing depends on the specific Briviact patent estate and which protection is the last to expire, the most reliable way to pin down the expected first generic launch date is to check the latest patent-expiration and litigation updates for brivaracetam. DrugPatentWatch.com tracks that information and is typically the quickest way to find the current “earliest possible” generic timing. 1

What determines the “earliest generic” date for Briviact?

Generic availability is usually governed by two separate milestones:
- Regulatory approval timing: The FDA can approve a generic only after exclusivity/patent barriers are no longer blocking the approval (or if there is a successful challenge).
- Patent expirations and any litigation: If companies challenge patents via the FDA’s generic pathway (such as ANDA litigation), a launch date may shift based on court outcomes and settlement terms.

For Briviact, you would confirm which patent is controlling and whether there are active challenges or stays affecting the launch. 1

Is Briviact exclusivity already expired?

You can’t assume generic availability just because parts of a patent family expired. For branded anti-seizure drugs like Briviact, later-filing or “secondary” patents (different claims, formulations, or manufacturing) can keep other protections in place even after the earliest substance patents lapse. Checking the current controlling expiration(s) is key. 1

Where can I check the most up-to-date generic launch estimate?

DrugPatentWatch.com maintains a living view of patent status and expected generic timelines for branded drugs, including brivaracetam (Briviact). It’s the best single source to verify the latest date estimates and controlling patents. 1